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The US Preventive Services Task Force recommends against
vitamin D and calcium supplementation for fracture prevention
in otherwise healthy postmenopausal women.1However, despite
high quality systematic reviews reporting ineffectiveness, many
guideline groups continue to recommend vitamin D
supplementation (with or without calcium) for fall or fracture
prevention. Recently Public Health England recommended that
everyone needs vitamin D equivalent to an average daily intake
of 10 μg (400 IU) to protect bone and muscle health,2 and more
than 30-50% of older people in some Western countries take
vitaminD supplements.3 4The role of vitaminD supplementation
in individuals not at high risk of osteomalacia (box 1) has been
extensively investigated in recent years, but some uncertainties
remain.
Since severe vitamin D deficiency causes osteomalacia (box 1),
it is reasonable to ask whether less marked reductions in
25-hydroxyvitamin D are associated with musculoskeletal
outcomes such as falls and fractures, or surrogate markers such
as bone density, muscle function, and parathyroid hormone.
Numerous observational studies have shown that low vitamin
D status is associated with these musculoskeletal outcomes.
These studies must be treated cautiously because observational
studies are subject to confounding, and low vitamin D status
might be a marker of poor health or lifestyle rather than a causal
factor.
Based on these associations, the next step is to ask whether
prescribing vitamin D to increase 25-hydroxyvitamin D levels
prevents or modifies these outcomes. Although clinical trials
show that vitamin D supplementation can lower parathyroid
hormone, it is unclear whether this is a valid surrogate for
clinical outcomes. Therefore, the effects of vitamin D
supplementationmust be determined from randomised controlled
trials (RCTs) with “hard” clinical outcomes. A large number of
RCTs andmeta-analyses with clinical outcomes have been done.
Observational and preclinical studies have also associated low
vitamin D status with a wide variety of non-skeletal adverse
clinical outcomes (box 2)6 7 that are not recognised features of
osteomalacia. Trial data and some meta-analyses are now
available to understand whether prescribing vitamin D to
increase 25-hydroxyvitamin D makes a difference for such
non-musculoskeletal outcomes.
What is the evidence of uncertainty?
Musculoskeletal outcomes
Vitamin D alone
Over 50 meta-analyses of vitamin D supplementation and falls
or fractures have been published; some report small beneficial
effects but others none. These results might seem inconsistent,
but the differences are largely explained by differences in
methodology. When all available RCTs are included, and all
participants from all the studies are analysed by intention-to-treat
(rather than “per protocol” or “completers” analyses), there is
no consistent evidence that vitamin D supplementation or raising
25-hydroxyvitamin D levels improves musculoskeletal
outcomes.8-10 In such systematic reviews, vitamin D
supplementation (when used as monotherapy without additional
calcium supplementation) had no important effects on bone
density11 nor any consistent effects on falls,12 total fracture, or
hip fracture (table 1⇓).13 Some individual trials reported
statistically significant, clinically relevant increased risks of
falls (range of relative risks 1.15-1.40)14 15 and fractures (range
of relative risks 1.26-1.49)14 16 from intermittent, high dose
vitamin D.
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What you need to know
• Meta-analyses of randomised controlled trials (RCTs) show that vitamin D supplementation alone does not improve musculoskeletal
outcomes
• Meta-analyses of randomised controlled trials of vitamin D on non-musculoskeletal outcomes suggest ongoing uncertainty:
– There is no high quality evidence to suggest that it is beneficial for these outcomes
– There is insufficient evidence to conclude firmly against small benefits, but RCT results exclude beneficial effects of a size suggested
by observational studies
– The clinical trials currently under way are unlikely to answer these uncertainties
BOX 1: Vitamin D facts
• Vitamin D is a prohormone synthesised in the skin in response to ultraviolet-B radiation in sunlight
• Dietary sources are limited and include oily fish, egg yolk, red meat, liver, and fortified breakfast cereals, fat spreads, and milk in some
countries
• Vitamin D is needed to ensure adequate intestinal absorption of calcium to maintain normal serum calcium levels
• The best current test for vitamin D status is serum 25-hydroxyvitamin D
• 25-hydroxyvitamin D level <25 nmol/L is classified as vitamin D deficiency. Classifications of vitamin D sufficiency vary, ranging from
≥50 nmol/L to ≥80 nmol/L
• Those at high risk of vitamin D deficiency include people who are housebound, have very limited sunlight exposure, or have severe
malabsorption syndromes
• In adults, severe vitamin D deficiency can cause osteomalacia:
– A syndrome of impaired bone mineralisation, bone fragility, and proximal myopathy
– Most likely when serum 25-hydroxyvitamin D level ≤15 nmol/L5
– Counsel individuals at high risk about sunlight exposure and diet, and consider use of low dose vitamin D supplements (400-800
IU/day)
Box 2: Examples of conditions associated with low vitamin D status in observational studies
Cancer—Breast cancer, colorectal cancer
Cardiovascular—Myocardial infarction, ischaemic heart disease, congestive heart failure, hypertension, venous thromboembolism
Gastrointestinal—Inflammatory bowel disease, chronic pancreatitis
Infection—Infections, sepsis, hepatitis C
Metabolic—Type 1 and type 2 diabetes, obesity, metabolic syndrome, dyslipidaemia
Mortality—All-cause mortality, cardiovascular mortality, cancer mortality
Musculoskeletal—All fractures, hip fractures, falls, osteoarthritis, rheumatoid arthritis, muscle strength, physical performance
Neurological—Multiple sclerosis, Alzheimer’s disease, cognitive decline, Parkinson’s disease, mood disorders and depression
Pregnancy related—Gestational diabetes, pre-eclampsia
Respiratory—Respiratory infections, tuberculosis, lung function, asthma, bronchiectasis
Other—Systemic lupus erythematosus, infertility, chronic pain, autism, hearing loss
Vitamin D with calcium
Results for co-administered vitamin D and calcium supplements
and fracture differ slightly from those for vitamin D
monotherapy.Meta-analyses report that co-administered vitamin
D and calcium prevented hip and non-vertebral fractures in two
trials of severely vitamin D deficient (mean baseline
25-hydroxyvitamin D 20 nmol/L) frail, elderly women in
residential care, but not in seven trials of community dwelling
older people.13When considering use of calcium in combination
with vitamin D, the benefits from preventing fracture should be
weighed against mild but common gastrointestinal side effects
and serious but uncommon side effects of kidney stones and
cardiovascular events.17
Non-skeletal outcomes
See box 2 for the range of potential non-skeletal outcomes.
Systematic reviews of RCTs show no consistent effect of
vitamin D supplementation on non-skeletal outcomes (table
2⇓).6-18 This evidence is less strong than for musculoskeletal
outcomes becausemost of the RCTswere designed and powered
to assess surrogate outcomes, but a wide range of clinical
outcomes have also been reported, albeit as secondary outcomes.
We can be reasonably certain that for the most common or
important conditions, these results exclude beneficial effects of
vitamin D supplementation of a size suggested by observational
studies. Although some meta-analyses have reported positive
effects of vitamin D supplementation for a few outcomes,
authors’ comments suggest that they do not consider the
evidence to be reliable enough to make definitive conclusions
(table 2⇓).
Is ongoing research likely to provide
relevant evidence?
We searched for ongoing large RCTs because they are most
likely to influence clinical practice. There are at least seven
ongoing large (n ≥1000) RCTs of vitamin D supplementation
with a variety of non-skeletal primary outcomes. These are
unlikely to alter conclusions from the current systematic reviews
for two reasons. Firstly, a technique that estimates the strength
and reliability of evidence from cumulative meta-analyses (trial
sequential analyses) suggest that existing trial evidence reliably
excludes clinically relevant (10-15%) reductions in relative risk
of falls, fractures, myocardial infarction, stroke, and cancer from
vitamin D supplementation and that new trial results are unlikely
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to alter these conclusions.12 18 Relative risk reductions of <10%
are unlikely to be attractive to individuals because the absolute
benefit of treatment is small, and there is a high likelihood of
no benefit from treatment.
Secondly, most of the participants in existing RCTs had baseline
25-hydroxyvitamin D levels of 25-50 nmol/L. If vitamin D
supplementation does have benefits, they are most likely to be
seen in populations with severe vitamin D deficiency. None of
the ongoing trials are targeting these population groups and are
therefore unlikely to recruit cohorts with baseline
25-hydroxyvitamin D levels <25 nmol/L.5
Some earlier trials have reported increased risk of falls or
fractures with high vitamin D doses.14-16 The ongoing large trials
are all using high daily or intermittent dose regimens and should
clarify whether such doses are harmful.
What should we do in the light of the
uncertainty?
Osteomalacia is an uncommon but serious illness that can readily
be prevented. People at high risk (box 1) should be counselled
about sunlight exposure and diet, and low dose vitamin D
supplements (400-800 IU/day) can be considered on an
individual basis. Otherwise, we conclude that current evidence
does not support the use of vitaminD supplementation to prevent
disease. This advice is similar to the recommendation of the
Scientific Advisory Committee on Nutrition that
25-hydroxyvitamin D of individuals in the UK should not fall
below 25 nmol/L.5 We believe this can be achieved
pragmatically by offering high risk individuals or populations
low dose vitamin D of 400-800 IU/day; measurement of
25-hydroxyvitamin D is seldom necessary.
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Search strategies and trial registries searched
Our article is based on repeated searches carried out independently by two authors (MJB and AA) to inform systematic reviews of vitamin
D published over several years with outcomes of fracture, falls, mortality, cardiovascular disease, stroke, cancer, and adverse events. The
full text of the searches are available in the primary references,12-18 but we have repeatedly searched Medline, PubMed, Embase, and the
Cochrane Library and hand searched reference lists and relevant conference abstracts for randomised controlled trials and systematic
reviews of vitamin D in adults. Our most recent search was in December 2015 to identify all published randomised controlled trials of vitamin
D supplementation. We also searched ClinicalTrials.gov (https://clinicaltrials.gov/), the International Standard Randomised Controlled Trial
Number (ISRCTN) registry (www.isrctn.com/), and the Australian New Zealand Clinical Trials Registry (ANZCTR) (www.anzctr.org.au/) for
completed and ongoing trials, using vitamin D as the search term.
Recommendations for future research
• Future randomised controlled trials of vitamin D supplementation should focus on populations with severe vitamin D deficiency by
enrolling individuals with 25-hydroxyvitamin D concentrations <25 nmol/L
• Such individuals would need to be at low risk of osteomalacia at baseline, and the trial protocol would need specific provision for
monitoring for osteomalacia. However, there will be costs from identifying sufficient numbers of participants with low 25-hydroxyvitamin
D
Education into practice
• If a middle aged patient who is otherwise well asks you whether they should take vitamin D what would you discuss with them to come
to a decision?
• If you saw a housebound older person, how would you consider and discuss the pros and cons of vitamin D with them?
• Based on reading this article is there anything that you would do differently in your practice?
How patients were involved in the production of this article
No patients were involved in the production of this article
Tables
Table 1| Recent meta-analyses of vitamin D monotherapy which show no statistically significant difference on musculoskeletal outcomes
Relative risk (95% CI)No of participantsNo of trialsOutcome
0.95 (0.89 to 1.02)22 29116Falls12
1.03 (0.96 to 1.11)28 27115Total fracture13
1.12 (0.98 to 1.29)27 69311Hip fracture13
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Table 2| Recent wide-ranging systematic reviews and Cochrane reviews of randomised controlled trials (RCTs) of vitamin D supplementation
with non-skeletal outcomes
FindingsDescriptionOutcomeReview
Comprehensive, large systematic reviews
• No effect on disease occurrence.
• Small reduction in all-cause mortality (RR range 0.93-0.96).
• Authors state that RCTs of disease reduction are needed to test
whether associations between low vitamin D status and ill health are
mediated by inflammation.
172 RCTsClinical and surrogate outcomes
(including cardiovascular disease,




• Does not reduce skeletal or non-skeletal outcomes by more than






• No consistent effects on health outcomes.87 meta-analyses of
RCTs
Clinical and surrogate outcomesTheodoratou 20147
Recent Cochrane reviews
• No effect on cancer incidence.
• Reduced cancer mortality in 4 trials (RR 0.88 (95%CI 0.78 to 0.98)),
but authors rated this low quality evidence
18 RCTsCancerBjelakovic 2014, (CD007469)
• Reduced mortality by small amount (RR 0.97 (95% CI 0.94 to 0.99)).
• Benefit in trials of vitamin D3 (RR 0.94 (0.91 to 0.98)) but not vitamin
D2 (RR 1.02 (0.96 to 1.08)).
• Authors state that risks of attrition bias, outcome reporting bias, and
other weaknesses warrant further placebo-controlled RCTs
56 RCTsMortalityBjelakovic 2014, (CD007470)
• Insufficient evidence to draw reliable conclusions3 RCTsCystic fibrosisFerguson 2014, (CD007298)
• Insufficient evidence to draw reliable conclusions but large effect
unlikely
10 RCTsChronic painStraube 2015, (CD007771)
• Insufficient evidence to draw reliable conclusions15 RCTsPregnancy and newborn outcomesDe-Regil 2016, (CD008873)
• In each trial, vitamin D had no effect on primary or secondary clinical
outcomes.
• Reduced rate of exacerbations requiring corticosteroids or hospital
visit. These were not the primary or secondary outcomes.
• Authors recommend caution in applying evidence to clinical practice
because results come from few trials.
7 RCTs (2 in adults)AsthmaMartineau 2016, (CD011511)
RCT = randomised controlled trial. RR = relative risk. CI = confidence interval.
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